Superpower peptides available for pre-order. Get first access.

FDA-approved

Hormones & metabolism

Albiglutide

EvidenceFDA approved
ClassGLP-1 receptor agonist

Key takeaway

Albiglutide is a once-weekly GLP-1 receptor agonist made by fusing GLP-1 analog chains to human albumin, approved for type 2 diabetes in 2014 as Tanzeum. It had a somewhat weaker effect on gastric emptying and appetite than some other GLP-1 drugs but showed a cardiovascular benefit in the HARMONY OUTCOMES trial. Despite that, GSK withdrew it from the market in 2018 for commercial reasons, so it remains FDA-approved but is no longer available.

Published
October 5, 2026
Last updated
October 5, 2026

At a glance

FDA statusFDA-approved GLP-1 peptide, formerly sold as Tanzeum for type 2 diabetes
How it's takenOnce-weekly injection made by fusing a GLP-1 analog to the blood protein albumin
Market statusWithdrawn by its manufacturer in 2018 for commercial reasons, despite a positive cardiovascular trial
Evidence strengthFDA approved

What is albiglutide?

Albiglutide is a GLP-1 receptor agonist1, a peptide that mimics the natural gut hormone GLP-1. It was engineered by fusing two GLP-1 analog chains to human albumin, the most abundant protein in blood, which extended its lifespan enough for once-weekly dosing.

It was made by GlaxoSmithKline and sold as Tanzeum, given as a once-weekly subcutaneous injection.

How does it work?

Albiglutide lowers blood sugar by activating the GLP-1 receptor, mimicking a gut hormone the body releases after eating. Through that receptor it:

  • Drives glucose-dependent insulin release1, which keeps the risk of hypoglycemia low on its own
  • Lowers glucagon
  • Slows the rate at which the stomach empties, though it has a somewhat weaker effect on gastric emptying and appetite than some other GLP-1 drugs

Fusing the peptide to albumin is what gave it a long half-life and once-weekly dosing. In the HARMONY OUTCOMES2 trial, albiglutide reduced major cardiovascular events in people with type 2 diabetes and established heart disease.

Is it FDA-approved?

Yes, but it is no longer sold. Tanzeum was approved in 2014 for type 2 diabetes. Despite the later HARMONY OUTCOMES trial showing a cardiovascular benefit, GSK withdrew3 Tanzeum from the market in 2018 because of low sales, so it remains FDA-approved but is not available.

What is albiglutide prescribed for?

When it was marketed, albiglutide was prescribed to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It was not a treatment for type 1 diabetes, and it was not recommended for people with a personal or family history of medullary thyroid carcinoma3 or Multiple Endocrine Neoplasia syndrome type 2.

What are the side effects?

The most common side effects were:

  • Diarrhea
  • Nausea
  • Injection-site reactions
  • Upper respiratory infection

Less common but more serious risks included:

  • Thyroid C-cell tumors: albiglutide carried a boxed warning3 based on rodent studies. It is not known whether this happens in humans.
  • Pancreatitis, or inflammation of the pancreas
  • Severe allergic reactions, including anaphylaxis
  • Low blood sugar, especially when combined with insulin or a sulfonylurea
  • Acute kidney injury, usually from dehydration caused by vomiting or diarrhea

More for hormones & metabolism

Sources: a published review of Tanzeum (albiglutide); the HARMONY OUTCOMES cardiovascular trial (Hernandez et al., The Lancet, 2018, DOI: 10.1016/S0140-6736(18)32261-X2), indexed on PubMed; and drug references documenting its 2018 market withdrawal. This document is educational and does not constitute medical advice.